Since my January 2024 article, Exelixis, Inc. (NASDAQ: EXEL ) has appreciated significantly. I believe this has been mostly due to Cabometyx’s continued success and its pipeline’s strategic progress. EXEL aims to become a genitourinary [GU] and gastrointestinal [GI] oncology leader. Its leading product is Cabometyx, aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer scie ...